Maplight Therapeutics (NASDAQ:MPLT) was upgraded by analysts at
Wall Str
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
Maplight Therapeutics (NASDAQ:MPLT) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Maplight Therapeutics (NASDAQ:MPLT) was upgraded by analysts at Zacks Research to a "hold" rating.